This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Corneal Disorders  • Ophthalmological Procedures, Other  • Transplantation, Other  • Drug Therapy  • Drug Therapy, Other  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lingyi Liang, MD, PhD; Hosam Sheha, MD, PhD; Scheffer C. G. Tseng, MD, PhD

Arch Ophthalmol. 2009;127(11):1428-1434.

Objective  To determine the long-term outcomes of keratolimbal allograft (KLAL).

Methods  Scores of such risks as infrequent blinking, blink-related microtrauma, conjunctival inflammation, elevated intraocular pressure, dry eye, symblepharon, lagophthalmos, and previous KLAL or penetrating keratoplasty (PKP) failure were calculated and recorded before, during, and after KLAL. Prolonged oral mycophenolate mofetil and tacrolimus and short-term prednisone and acyclovir were administered in 12 eyes (10 consecutive patients) with total limbal stem cell deficiency after KLAL. Ten eyes underwent subsequent PKP.

Results  More corrective measures were required in eyes with higher risk scores. During a follow-up of 61.2 months (standard deviation [SD], 18.2; range, 36-91 months) after KLAL, postoperative epithelial breakdown due to exposure occurred late in the period after PKP and remained a primary risk. Mean daily doses of 1.4 g of mycophenolate mofetil and 1.6 mg of tacrolimus were administered for 52.7 months (SD, 22.5; range, 23-91 months) with few adverse effects and reached trough levels of 1.6 µg/mL (SD, 0.6 µg/mL) and 4.5 ng/mL (SD, 2 ng/mL), respectively. Keratolimbal allograft and PKP rejection was noted in 2 and 3 eyes, respectively, though there was a reversal in 1 eye in each group, yielding final KLAL and PKP survivals in 10 and 8 eyes, respectively, and ambulatory visual acuity of up to 20/20 in 10 eyes for 67.2% of the entire follow-up period.

Conclusion  Correction of ocular surface deficits combined with an immunosuppressive regimen further improves the long-term outcome of KLAL in eyes with total limbal stem cell deficiency.

Author Affiliations: State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Ocular Surface Disease Center, Sun Yat-sen University, Guangzhou, China (Dr Liang); Ocular Surface Center, Ocular Surface Research and Education Foundation, Miami, Florida (Drs Liang, Sheha, and Tseng); and Research Institute of Ophthalmology, Cairo, Egypt (Dr Sheha).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?